

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 12th June 2025

FOI Ref No 29167

Requested Information:

Regarding the treatment of renal cell carcinoma. Could you please answer the following questions:

1) How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :

- Avelumab + Axitinib
- Axitinib
- Cabozantinib
- Everolimus
- Lenvatinib + Everolimus
- Lenvatinib + Pembrolizumab
- Nivolumab monotherapy
- Nivolumab + Cabozantinib
- Nivolumab + Ipilimumab
- Pazopanib
- Pembrolizumab monotherapy
- Pembrolizumab + Axitinib
- Radiotherapy only
- Sunitinib
- Temsirolimus
- Tivozanib
- Other active systemic anti-cancer therapy
- Palliative care only

2) In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

- Avelumab + Axitinib (Bavencio + Inlyta)
- Cabozantinib (Cometriq)
- Nivolumab (Opdivo)
- Nivolumab + Cabozantinib (Opdivo + Cometriq)
- Nivolumab + Ipilimumab (Opdivo + Yervoy)
- Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda)

3) In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab (monotherapy)
- Nivolumab + Ipilimumab
- Nivolumab + Cabozantinib
- Avelumab + Axitinib
- Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

4) In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

5) Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?

Response:

Regarding the treatment of renal cell carcinoma. Could you please answer the following questions:

1) How many patients have been treated in the past 3 months (February 2025 to April 2025) with the following agents for renal cell carcinoma (any stage) :

- Avelumab + Axitinib **4**
- Axitinib **0**
- Cabozantinib **10**
- Everolimus **0**
- Lenvatinib + Everolimus **4**
- Lenvatinib + Pembrolizumab **8**
- Nivolumab monotherapy **7 (6 of these are maintenance after ipi/nivo induction)**
- Nivolumab + Cabozantinib **4**
- Nivolumab + Ipilimumab **4**
- Pazopanib **4**

- Pembrolizumab monotherapy **17**
- Pembrolizumab + Axitinib **0**
- Radiotherapy only **0**
- Sunitinib **0**
- Temsirolimus **0**
- Tivozanib **0**
- Other active systemic anti-cancer therapy **2**
- Palliative care only **1**

2) In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

- Avelumab + Axitinib (Bavencio + Inlyta) **4**
- Cabozantinib (Cometriq) **4**
- Nivolumab (Opdivo) **6**
- Nivolumab + Cabozantinib (Opdivo + Cometriq) **4**
- Nivolumab + Ipilimumab (Opdivo + Yervoy) **4**
- Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda) **8**

3) In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab (monotherapy) **0**
- Nivolumab + Ipilimumab **3**
- Nivolumab + Cabozantinib **0**
- Avelumab + Axitinib **0**
- Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda) **0**

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

4) In the last 3 months (February to April 2025), how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

- **18 patients have undergone one of these procedures of whom 7 were for cancer treatment.**

5) Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?

- **Please see appendix one**

Attachment(s):

Appendix One - FOI Ref 29167 Renal Cell Carcinoma Clinical Trials

Date Response sent: 25th June 2025